Seeking Alpha

Rigel Pharmaceuticals (RIGL -9.5%) drops after a hard miss on its Q4 EPS. Operating expenses...

Rigel Pharmaceuticals (RIGL -9.5%) drops after a hard miss on its Q4 EPS. Operating expenses soared 25% Y/Y, primarily due to the increase in R&D expenses related to R343, its inhaled inhibitor program for asthma, and R333, its topical inhibitor program for lupus.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)